Simulated interactions between a Class III antiarrhythmic drug and a figure 8 reentry
R G Seigneuric1, J-L Chassé, P Auger
1Maastro Lab, University of Maastricht, UNS 50/23, PO Box 616, 6200, MD Maastricht, The Netherlands. r.seigneuric@maastro.unimaas.nl
Abstract:
Ventricular Fibrillation is responsible for a majority of sudden cardiac death, but little is known about how ventricular tachycardia (VT) degenerates into ventricular fibrillation. Several clinical studies focused only on preventing VT with a class III antiarrhythmic drug resulted in many deaths. Our simulations investigate the interactions between an antiarrhythmic drug likely to suppress a VT and a Figure 8 reentry. A parameter AAR is introduced to increase the action potential duration and therefore simulate various Class III drugs. Simulations are ran under several conditions (phases of the reentry, values of AAR, durations). They show that a VT can be suppressed whatever the phase of the reentry but it strongly depends on the duration of the effect. It confirms that a drug which can suppress a reentry can also worsen it. It also shows a great variety of activation patterns and thus the complexity of antiarrhythmic drugs effects. Simulations also demonstrate that suppressing VT is an increasing function of AAR.
Insights
Ventricular tachycardia (VT) degeneration into ventricular fibrillation is complex. Simulations show antiarrhythmic drug duration, not just type, critically impacts VT suppression, highlighting potential risks.
Area of Science:
- Cardiology
- Computational Biology
- Pharmacology
Background:
- Ventricular fibrillation causes most sudden cardiac deaths, yet VT degeneration mechanisms remain unclear.
- Previous clinical trials using Class III antiarrhythmics to prevent VT led to increased mortality.
- Understanding drug interactions with reentrant circuits is crucial for patient safety.
Purpose of the Study:
- To investigate the interaction between antiarrhythmic drugs and Figure 8 reentry.
- To simulate the effects of Class III antiarrhythmic drugs on ventricular tachycardia (VT).
- To explore the influence of drug duration and action potential duration on VT suppression.
Main Methods:
- Computational simulations were employed to model drug effects.
- A parameter, action potential *ab*normal duration (AAR), was introduced to represent Class III drugs.
- Simulations analyzed various reentry phases, AAR values, and drug durations.
Main Results:
- VT suppression is achievable across different reentry phases but highly dependent on drug effect duration.
- Simulations confirmed that drugs suppressing reentrant circuits can also exacerbate them.
- A wide range of activation patterns demonstrated the complexity of antiarrhythmic drug actions.
Conclusions:
- Drug duration is a critical factor in suppressing VT, not solely the drug's ability to suppress reentrant circuits.
- Antiarrhythmic drug efficacy in suppressing VT increases with higher AAR values.
- These findings underscore the complex and potentially dual effects of antiarrhythmic drugs, necessitating careful consideration of drug duration in clinical practice.
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:25Dysrhythmias VI: Management of Dysrhythmias
01:30Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials